Results 81 to 90 of about 22,264 (222)

Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura [PDF]

open access: yes, 2013
Complement dysregulation is key in the pathogenesis of atypical Haemolytic Uraemic Syndrome (aHUS), but no clear role for complement has been identified in Thrombotic Thrombocytopenic Purpura (TTP).
Heelas, E   +4 more
core   +1 more source

Fulminant myocarditis in immune‐mediated thrombotic thrombocytopenic purpura: A case report

open access: yesAcute Medicine & Surgery
Background Thrombotic thrombocytopenic purpura is a life‐threatening thrombotic microangiopathy characterized by systemic microvascular thrombosis. Cardiovascular complications, including myocardial ischemia and necrosis, are a leading cause of acute ...
Haruka Ishikita   +5 more
doaj   +1 more source

Guidance for Documentation of Therapeutic Apheresis Interventions in the Medical Record: An American Society for Apheresis (ASFA) Practice Perspective

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 2, April 2026.
ABSTRACT In 2007, the American Society for Apheresis (ASFA) published guidance for physician documentation related to oversight of therapeutic apheresis (TA). Due to 21st century changes in healthcare delivery, the ASFA Board of Directors (BOD) charged its Public Affairs and Advocacy Committee (PAAC) to coordinate a review and update of the guidance ...
Chester Andrzejewski   +8 more
wiley   +1 more source

Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition [PDF]

open access: yes, 2015
Introduction Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a disease characterized by hemolytic anemia, thrombocytopenia, and renal impairment. Gemcitabine, a commonly used chemotherapy, is emerging as a cause of aHUS.
Karkowsky, MD, Raphael   +1 more
core   +2 more sources

Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature

open access: yesCase Reports in Medicine, 2014
Introduction. Sunitinib malate is an oral multitargeting tyrosine kinase inhibitor approved for the first line treatment of metastatic renal cell carcinoma.
Imane El Dika   +4 more
doaj   +1 more source

Successful Treatment of Aplastic Anemia With Eltrombopag During Pregnancy: A Short Report

open access: yeseJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Introduction Aplastic anemia (AA) is a rare bone marrow failure syndrome with pancytopenia, mainly due to immune‐mediated stem cell destruction. First‐line therapy for acquired severe AA ≥ 50 years/non‐severe AA (NSAA) requiring treatment is immunosuppressive therapy with horse anti‐thymocyte globulin, cyclosporine A (CSA), and eltrombopag ...
Sandra M. Frey   +3 more
wiley   +1 more source

Thrombotic thrombocytopenic purpura: Description and analysis of 23 cases treated in Chile between 2017 and 2022

open access: yesMedwave
Introduction Since the first description of Thrombotic Thrombocytopenic Purpura, caused by a severe deficiency of ADAMTS13, plasma exchange and immunosuppression have become standard treatments, allowing to decrease its high mortality rate.
Daniel Cathalifaud   +6 more
doaj   +1 more source

Presumptive thrombotic thrombocytopenic purpura following a hump-nosed viper (Hypnale hypnale) bite: a case report

open access: yesJournal of Venomous Animals and Toxins including Tropical Diseases, 2014
Hump-nosed viper bites are frequent in southern India and Sri Lanka. However, the published literature on this snakebite is limited and its venom composition is not well characterized.
Milinda Withana   +3 more
doaj   +1 more source

Tuberculosis presenting as immune thrombocytopenic purpura [PDF]

open access: yes, 2004
Background Although various hematologic abnormalities are seen in tuberculosis, immune thrombocytopenic purpura is a rare event. Case Presentation We report a case of a 29 year-old male who was presented with immune thrombocytopenia-induced hemoptysis ...
Bahadir-Erdogan Beril   +7 more
core   +2 more sources

Home - About - Disclaimer - Privacy